
CombiGene launches new website

Expanded information on the latest progress within the epilepsy project CG01 and the company's new lipodystrophy project

During the last weeks, CombiGene has taken several significant steps forward. The development can be summarized as follows: our epilepsy project CG01 took two important steps towards clinical studies when we made our definitive choice of CRO and CDMO partners, and we will finalize the projects pre-clinical phase with the biodistribution and toxicology studies that are planned for the second half of 2020.

Our project portfolio has increased by one additional project – the lipodystrophy project. And we have, with the acquisition of Panion Animal Health, now full control of all IP related to the CG01 project, which is important in negotiations with potential partners.

All in all, this means that we now have a broader and even more interesting project portfolio, that the road towards clinical studies for CG01 is staked out, and that we are better equipped in our discussions with future partners.

Based on the above, we have updated our web site with new and expanded information on CombiGene's projects. We encourage everybody to visit it. And – please tell your friends and family about CombiGene and gene therapy. We want as many as possible to join us on the exciting research journey that lies ahead.

Jan Nilsson
CEO

Contacts

Jan Nilsson, CEO
Phone: +46 (0)704 66 31 63
jan.nilsson@combigene.com

Arne Ferstad, Chairman of the board
Phone: +447496526142
arne.ferstad@combigene.com

www.combigene.com
CombiGene AB (publ) Medicon Village, SE-223 81 Lund, Sweden
info@combigene.com

About CombiGene

CombiGene's vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies.

CombiGene's business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations.

The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company's Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99, info@fnca.se.

CombiGene's lead project CG01 has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 823282

Attachments

[Combigene PM 20191016 Ny Website EN](#)
[CombiGene launches new website](#)